Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6495-6507
DOI: 10.1021/acs.jmedchem.3c02416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.04.2024. Verfasst von Yugendar R Alugubelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M Drug Discovery Center, Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Proteolysis, Coronavirus 3C Proteases. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIBIB NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
We have witnessed three coronavirus (CoV) outbreaks in the past two decades, including the COVID-19 pandemic caused by SARS-CoV-2. Main protease (MPro), a highly conserved protease among various CoVs, is essential for viral replication and pathogenesis, making it a prime target for antiviral drug development. Here, we leverage proteolysis targeting chimera (PROTAC) technology to develop a new class of small-molecule antivirals that induce the degradation of SARS-CoV-2 MPro. Among them, MPD2 was demonstrated to effectively reduce MPro protein levels in 293T cells, relying on a time-dependent, CRBN-mediated, and proteasome-driven mechanism. Furthermore, MPD2 exhibited remarkable efficacy in diminishing MPro protein levels in SARS-CoV-2-infected A549-ACE2 cells. MPD2 also displayed potent antiviral activity against various SARS-CoV-2 strains and exhibited enhanced potency against nirmatrelvir-resistant viruses. Overall, this proof-of-concept study highlights the potential of targeted protein degradation of MPro as an innovative approach for developing antivirals that could fight against drug-resistant viral variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Texas A&M Drug Discovery Center, Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
- Department of Biology, Texas A&M University, College Station, Texas 77843, United States.
- Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch, Galveston, Texas 77555, United States.
- Texas A&M Global Health Research Complex, Texas A&M University, College Station, Texas 77843, United States.
- Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, United States.
- Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, Texas 77030, United States.
ORCID-Profile: Long Sun, Xinyu R Ma, Benjamin W Neuman, Wenshe Ray Liu, Shiqing Xu
Förderung
- NIAID NIH HHS
- NIBIB NIH HHS
- NIGMS NIH HHS
- Amon G. Carter Foundation
- Welch Foundation
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- Texas A and M University
- National Institutes of Health
Zitieren
APA
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Sun, L., Ma, Y., Ma, X. R., Vulupala, V. R., Atla, S., Blankenship, L. R., Coleman, D., Xie, X., Neuman, B. W., Liu, W. R., & Xu, S. (2024). Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry, 67(8), 6495-6507. https://doi.org/10.1021/acs.jmedchem.3c02416
Vancouver
Alugubelli YR, Xiao J, Khatua K, Kumar S, Sun L, Ma Y, et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 2024;67(8):6495-6507. doi:10.1021/acs.jmedchem.3c02416
BibTeX
@article{Alugubelli2024,
author = {Alugubelli, Yugendar R and Xiao, Jing and Khatua, Kaustav and Kumar, Sathish and Sun, Long and Ma, Yuying and Ma, Xinyu R and Vulupala, Veerabhadra R and Atla, Sandeep and Blankenship, Lauren R and Coleman, Demonta and Xie, Xuping and Neuman, Benjamin W and Liu, Wenshe Ray and Xu, Shiqing},
title = {Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {8},
pages = {6495--6507},
doi = {10.1021/acs.jmedchem.3c02416}
}
EUVIMED